Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: The GPOH-HD-2002 study

Journal of Clinical Oncology

Volumn 28, Issue 23, 2010, Pages 3680-3686

  Mauz Körholz, Christine ^a   Hasenclever, Dirk ^a   Dörffel, Wolfgang ^a   Ruschke, Kathrin ^a   Pelz, Tanja ^a   Voigt, Antje ^a   Stiefel, Martina ^a   Winkler, Melanie ^a   Vilser, Constanze ^a   Dieckmann, Karin ^a   Karlén, Jonas ^a   Bergsträsser, Eva ^a   Fosså, Alexander ^a   Mann, Georg ^a   Hummel, Michael ^a   Klapper, Wolfram ^a   Stein, Harald ^a   Vordermark, Dirk ^a   Kluge, Regine ^a   Körholz, Dieter ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT; AOPE PROTOCOL; OPPA PROTOCOL;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CHILD; CLASSICAL HODGKIN LYMPHOMA; CONSTIPATION; DRUG EFFICACY; DRUG TOLERABILITY; EVENT FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RADIATION DOSE; SCHOOL CHILD; SENSORY NEUROPATHY; STOMATITIS; THROMBOCYTOPENIA; HODGKIN DISEASE; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FEMALE; HODGKIN DISEASE; HUMANS; MALE; PREDNISONE; PROCARBAZINE; TREATMENT OUTCOME; VINCRISTINE;

EID: 77957268672     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.9381     Document Type: Article

References (36)

1. Schellong G, Waubke-Landwehr AK, Langermann HJ, et al: Prediction of splenic involvement in children with Hodgkin's lymphoma: Significance of clinical and intraoperative findings - A retrospective statistical analysis of 154 patients in the German therapy study DAL-HD-78. Cancer 57:2049-2056, 1986 (Pubitemid 16113785)
2. Schellong G, Brämswig J, Ludwig R, et al: Combined treatment strategy in over 200 children with Hodgkin's lymphoma: Graduated chemotherapy, involved field irradiation with low dosage and selective splenectomy - A report of the cooperative therapy study DAL-HD-82. Klin Pädiatr 198:137-146, 1986 (Pubitemid 16098805)
3. Schellong G, Hörnig I, Brämswig J, et al: Significance of procarbazine in the chemotherapy of Hodgkin's disease: A report of the Cooperative Therapy Study DAL-HD-85. Klin Pädiatr 200:205-213, 1988
4. Schellong G, Hörnig-Franz I, Rath B, et al: Reducing radiation dosage to 20-30 Gy in combined chemo-/radiotherapy of Hodgkin's lymphoma in childhood: A report of the cooperative DAL-HD-87 therapy study. Klin Pädiatr 206:253-262, 1994 (Pubitemid 24248161)
5. Schellong G, Pötter R, Brämswig J, et al: High cure rates and reduced long-term toxicity in pediatric Hodgkin's lymphoma: The German-Austrian multicenter trial DAL-HD-90 - The German-Austrian Pediatric Hodgkin's Disease Study Group. J Clin Oncol 17:3736-3744, 1999
6. Dörffel W, Lüders H, Rühl U, et al: Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's lymphoma in children and adolescents: Analysis and outlook. Klin Pädiatr 215:139-145, 2003 (Pubitemid 36718285)
7. Schellong G: Treatment of children and adolescents with Hodgkin's lymphoma: The experience of the German-Austrian Paediatric Study Group. Baillieres Clin Haematol 9:619-634, 1996
8. Schellong G, Riepenhausen M: Spätfolgen nach Morbus Hodgkin bei Kindern und Jugendlichen. Ergebnisse der Studien DAL-HD-78 bis -HD-90, 2002; Projektbericht. Münster, Germany, Eigenverlag, 2002
9. Metzger ML, HudsonMM:Balancing efficacy and safety in the treatment of adolescents with Hodgkin's lymphoma. J Clin Oncol 27:6071-6073, 2009
10. Hancock SL, Donaldson SS, Hoppe RT: Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol 11:1208-1215, 1993 (Pubitemid 23199121)
11. Meadows AT, Obringer AC, Marrero O, et al: Second malignant neoplasms following childhood Hodgkin's disease: Treatment and splenectomy as risk factors. Med Pediatr Oncol 17:477-484, 1989 (Pubitemid 20018259)
12. Schellong G, Riepenhausen M, Creutzig U, et al: Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease: German-Austrian Pediatric Hodgkin's Disease Group. J Clin Oncol 15:2247-2253, 1997 (Pubitemid 27251125)
13. Chabner BA, Longo DL (eds): Cancer Chemotherapy and Biotherapy: Principles and Practice. Philadelphia, PA, Lippincott-Raven, 1996, p 32
14. Kreuser ED, Xiros N, Hetzel WD, et al: Reproductive and endocrine gonadal capacity in patients treated with COPP chemotherapy for Hodgkin's disease. J Cancer Res Clin Oncol 113:260-266, 1987 (Pubitemid 17120601)
15. Brämswig JH, Heimes U, Heiermann E, et al: The effects of different cumulative doses of chemotherapy on testicular function: Results in 75 patients treated for Hodgkin's disease during childhood or adolescence. Cancer 65:1298-1302, 1990 (Pubitemid 20097151)
16. Gerres L, Brämswig JH, Schlegel W, et al: The effects of etoposide on testicular function in boys treated for Hodgkin's disease. Cancer 83:2217-2222, 1998 (Pubitemid 28525405)
17. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339:1506-1514, 1998
18. Kollmannsberger C, Beyer J, Droz JP, et al: Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol 16:3386-3391, 1998 (Pubitemid 28481637)
19. Whitlock JA, Greer JP, Lukens JN: Epipodophyllotoxin-related leukemia: Identification of a new subset of secondary leukemia. Cancer 68:600-604, 1991
20. Winick NJ, McKenna RW, Shuster JJ, et al: Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol 11:209-217, 1993 (Pubitemid 23046809)
21. Viviani S, Santoro A, Ragni G, et al: Gonadal toxicity after combination chemotherapy for Hodgkin's disease: Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol 21:601-605, 1985 (Pubitemid 15116991)
22. Viviani S, Ragni G, Santoro A, et al: Testicular dysfunction in Hodgkin's disease before and after treatment. Eur J Cancer 27:1389-1392, 1991
23. Frei E 3rd, Luce JK, Talley RW, et al: 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC- 45388) in the treatment of lymphoma. Cancer Chemother Rep 56:667-670, 1972
24. Klener P, Donner L: Imidazole carboxamide (DTIC) in the treatment of advanced lymphomas: Efficacy of DTIC in cases which fail to respond to conventional chemotherapeutic combinations. Acta Haematol 57:272-278, 1977 (Pubitemid 8066184)
25. Carter SK, Livingston RB: Single-agent therapy for Hodgkin's disease. Arch Intern Med 131: 377-387, 1973
26. Kaatsch P, Spix J: German Childhood Cancer Registry: Annual report 2006/07 (1980-2006). Mainz, Germany, Institute for Medical Statistics, Epidemiology, and Informatics, University Mainz, 2008. http://www. kinderkrebsregister.de
27. Steliarova-Foucher E, Kaatsch P, Lacour B, et al: Quality, comparability and methods of analysis of data on childhood cancer in Europe (1978-1997): Report from the ACCIS project. Eur J Cancer 42: 1915-1951, 2006
28. Kaatsch P, Haaf G, Michaelis J: Childhood malignancies in Germany: Methods and results of a nationwide registry. Eur J Cancer 31A:993-999, 1995
29. Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994 (Pubitemid 24273002)
30. Harris NL, Jaffe ES, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849, 1999
31. Trotti A, Byhardt R, Stetz J, et al: Common toxicity criteria: Version 2.0 - An improved reference for grading the acute effects of cancer treatment: Impact on radiotherapy. Int J Radiat Oncol Biol Phys 47:13-47, 2000 (Pubitemid 30179675)
32. Mauz-Körholz C, Gorde-Grosjean S, Hasenclever D, et al: Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma: Experience from the European Network Group on Pediatric Hodgkin Lymphoma. Cancer 110:179-185, 2007 (Pubitemid 46986431)
33. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
34. Peto R, Peto J: Asymptotically efficient rank invariant test procedures. J R Stat Soc A 135:185-207, 1972
35. Körholz D, Wallace WH, Landman-Parker J: EuroNet-Paediatric Hodgkin's Lymphoma Group (EuroNet-PHL-C1): First international inter-group study for classical Hodgkin's lymphoma in children and adolescents. http://clinicaltrials.gov/ct/show/NCT00433459
36. Hodgson NC, Button J, Solorzano CC: Thyroid cancer: Is the incidence still increasing? Ann Surg Oncol 11:1093-1097, 2004